Sonendo

Sonendo, Inc. is a medical technology company that has developed and is commercializing the GentleWave System to treat tooth decay. It offers practice management software to enable an integrated digital office for dental practitioners. The company was founded by Olav B. Bergheim in 2006 and is headquartered in Laguna Hills, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Sonendo reports robust Q4 earnings, eyes GP market expansion

Sonendo's Q4 2022 performance reflects strong revenue growth, milestone achievements, and strategic initiatives aimed at driving profitability and market expansion.
The company's focus on innovation, pricing strategies, and market diversification positions it well for sustained growth and competitive advantage in the dental technology sector.
While facing challenges in adoption transitions and market expansion, Sonendo has opportunities to capitalize on product innovation, market expansion, and strategic investments for future success.
Overall, Sonendo's performance, strengths, challenges, and opportunities indicate a positive outlook for continued growth, profitability, and market leadership in the dental technology industry.

Sonendo reports robust Q1 performance, eyes growth in GP market

Sonendo's Q1 2023 performance showed strong revenue growth and improved gross margins.
The company is capitalizing on the market interest in GentleWave consoles, especially the new G4 systems.
Challenges include longer sales cycles and the need to adapt to changing customer mindsets.
Opportunities lie in expanding market reach among general practitioners and enhancing operational efficiencies.

Sonendo reports $11M revenue in Q2 2023, focuses on margin improvement

Sonendo's Q2 2023 performance showed revenue growth driven by PI sales but offset by declining console revenue, with a focus on margin improvement and expense management.
Strengths include strong PI sales growth, initiatives to enhance margins, and strategic efforts to educate GPs about the GentleWave procedure.
Challenges include declining console placements, expense management actions, and revised revenue guidance due to sales cycle elongation.
Opportunities lie in leveraging PI sales growth, educating GPs, improving margins, and adapting to market dynamics for future growth and profitability.

Sonendo reports revenue growth amidst challenges, eyes market expansion

Sonendo's Q3 performance showed revenue growth but with high operating expenses.
The company is focusing on revenue growth, margin improvement, and cash preservation.
Challenges include declining consumable sales and ongoing debt covenant discussions.
Opportunities lie in market expansion, margin enhancement, and cost reduction efforts.

Sonendo reports mixed Q4 results, sets ambitious targets for 2024

Sonendo's 2023 performance showed revenue growth and margin improvement, with strategic divestments and debt restructuring enhancing financial flexibility.
While facing challenges in specific product sales and cost management, the company aims to capitalize on growth opportunities in 2024.
Clear communication on guidance, margins, and strategies can position Sonendo for sustainable growth and profitability in the coming year.

Sonendo exceeds Q1 revenue target, focuses on margin expansion

Sonendo's Q1 2024 earnings call highlighted a solid performance, operational strengths, challenges in revenue diversification, and opportunities for growth.
The company's focus on cost-saving measures, margin expansion, and strategic initiatives positions them well for future success and market competitiveness.
Investors should monitor Sonendo's execution of their strategic plan and revenue diversification efforts to assess long-term sustainability and growth potential.

Sonendo reports strong Q2 performance, raises revenue guidance

Sonendo's Q2 2024 performance reflects positive momentum and strategic alignment with growth objectives.
The company's focus on innovation, cost optimization, and revenue growth positions it well for future success.
While challenges exist, Sonendo's proactive approach and market opportunities bode well for sustained performance.
Overall, Sonendo's financial health and operational improvements signal a promising outlook for investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonendo, Inc. is a medical technology company, which developed and manufactures the GentleWave System to treat tooth decay. It operates through the Product and Software segments. The Product segment includes the sales of the GentleWave System console and related accessories and instruments. The Software segment focuses on the sales of traditional software licenses for practice management software to enable an integrated digital office for endodontists. The company was founded by Olav B. Bergheim in June 2006 and is headquartered in Laguna Hills, CA.

The stock price of Sonendo Inc (NYSE: SONX) increased by 21.18% today. This is why it happened.

Sonendo Stock (SONX): Why The Price Surged Today

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced certain unaudited preliminary revenue results for the fourth quarter and full-year ended December 31, 2021. The company expects to report revenue in the range of $9.7 million to $9.9 million for the fourth quarter of 2021: Product revenue is expected to be in the range of $7.5 million to $7.7 million for the fourth quarter of

Sonendo, Inc. Announces Preliminary Revenue Results for the Fourth Quarter and Full-Year 2021

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Total revenue of $7.9 million for the third quarter of 2021, representing growth of 29% compared to prior year period GentleWave console revenue of $1.8 million for the third quarter 2021, representing growth of 44% compared to prior year period Procedure instrum

Sonendo Inc. Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Revenue Guidance

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (NYSE: SONX) (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of Raj Pudipeddi as a member of its Board of Directors. Raj currently serves as Chief Product and Marketing Officer, Senior Vice President and Managing Director of the Asia Pacific region for Align Technology, a leading global medical device company that designs, manufactures, and sells the Invisalign system o

Sonendo Appoints Raj Pudipeddi to Board of Directors

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report finical results for the third quarter 2021 after the market close on Thursday, December 9, 2021. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialin

Sonendo, Inc. to Report Third Quarter 2021 Financial Results on December 9, 2021

LAGUNA HILLS, Calif., Nov. 16, 2021 /PRNewswire/ -- Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced the appointment of Alma Salazar as its Associate Vice President, Professional and Consumer Marketing.

Sonendo Announces Alma Salazar as Associate Vice President, Professional and Consumer Marketing

LAGUNA HILLS, Calif., Nov. 10, 2021 /PRNewswire/ -- Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced it has treated over 700,000 patients with its GentleWave® System, an alternative to traditional root canal therapy (RCT) backed by years of research and peer-reviewed clinical outcomes.

Sonendo's GentleWave Surpasses 700,000 Treatments, Solidifying Procedure as Alternative to Traditional Root Canal Therapy

Sonendo has gone public in an offering which has been a big disappointment as investors rightfully have concerns about growth and losses. I like the potential of the system, but as commercial traction is lagging with a huge market opportunity ahead, I am joining that cautious stance.

Sonendo: Painful Debut For This Dental Play

Leading dental technology company welcomes talented executives with substantial leadership experience spanning finance, accounting, human resources, and business operations LAGUNA HILLS, Calif., Nov. 3, 2021 /PRNewswire/ -- Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced the appointment of three new members to its Board of Directors.

Sonendo Appoints Three New Members to Board of Directors

Arteris

AirSculpt Technologies

Augmedix

Aura Biosciences

Solo Brands

Fluence Energy

GlobalFoundries

HireRight GIS Group Holdings LLC

LF Capital Acquisition Corp II

Marpai

Rent the Runway

Entrada Therapeutics

Udemy

Sweetgreen

The IPO market remained active this past week as 13 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion.

U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week

Sonendo Inc, a medical device system for less-invasive root canal therapy, raised $94 million via an IPO by offering 7.8 million shares at $12, below the range of $15 to $17.

Dental Tech Firm Sonendo Makes Its NYSE Debut

News for Sonendo Stock (SONX)